These Analysts Increase Their Forecasts On PTC Therapeutics

Core Insights - PTC Therapeutics has received FDA approval for SEPHIENCE, a significant milestone for patients with PKU [1] - The CEO emphasized the potential of SEPHIENCE to address unmet needs in PKU treatment and the company's readiness to launch the therapy [1] - Following the announcement, PTC Therapeutics shares increased by 11.7%, reaching $49.53 [1] Analyst Reactions - UBS analyst Colin Bristow maintained a Buy rating and raised the price target from $71 to $80 [7] - Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating and increased the price target from $112 to $120 [7] - Wells Fargo analyst Tiago Fauth also maintained an Overweight rating, raising the price target from $74 to $78 [7] - Barclays analyst Gena Wang maintained an Equal-Weight rating and raised the price target from $42 to $46 [7]